Orexo and SVF Vaccines Partner on AmorphOX for mRNA Vaccines
The partnership ultimately seeks to determine
The scientific collaboration aims to test if AmorphOX can create stable powder formulations through spray drying. Success depends on preserving the essential properties of nanoparticles and the functional activity of the RNA.
Lipid nanoparticles protect RNA and help transport it into cells. However, maintaining the stability of both the RNA molecule and the lipid vehicle remains a major hurdle. This instability complicates global storage and distribution logistics. Powder-based formulations could solve these challenges. They offer superior flexibility in handling, shipping, and storage.
This joint initiative combines Orexo's expertise in powder formulation and intranasal delivery with the vaccine development experience of SVF Vaccines. Positive feasibility results could pave the way for intranasal administration. That next phase would require careful evaluation of delivery performance, tolerability, and mucosal immune responses.
The partnership ultimately seeks to determine if AmorphOX can conquer a critical formulation bottleneck in RNA vaccines.
Leadership Perspectives on the Partnership
Nikolaj Sørensen, President and CEO of Orexo AB, commented on the goals of the project. He stated that their initial objective is to see if they can develop stable powder formulations. They must preserve lipid nanoparticle integrity and RNA activity. Favorable results would create a solid foundation for future development. It would also allow them to test their technology in vaccines and other biological applications.
Matti Sällberg, founder and Chief Scientific Officer at SVF Vaccines, also shared his perspective. He noted that the clinical success of RNA vaccines highlighted both their immense promise and their formulation hurdles. Transforming LNP-mRNA treatments into stable dry powders suitable for nasal delivery would mark a major breakthrough.
Intranasal vaccination creates immunity right where respiratory pathogens enter the human body. Sällberg emphasized that this partnership is a crucial first step. It unites their capabilities in RNA vaccines with Orexo's advanced formulation platform.
This alliance aligns directly with Orexo's broader corporate strategy. The company continuously tests AmorphOX across new therapeutic areas and novel molecule classes. The outcome of this initial feasibility program will dictate future development plans. It will also determine if the two companies expand their collaboration moving forward.